AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Assessment of Relative Bioavailability of NKTR-118 in Three Formulations in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: NKTR118 Formulation 1aDrug: NKTR118 Formulation 2Drug: NKTR118 Formulation 3aDrug: NKTR118 Formulation 1Drug: NKTR118 Formulation 3
- First Posted Date
- 2011-06-03
- Last Posted Date
- 2014-10-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 21
- Registration Number
- NCT01365000
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
A Study to Evaluate the Effect of Roflumilast on Airway Inflammation and Function Following Allergen Challenge in Subjects With Allergic Asthma
- First Posted Date
- 2011-06-03
- Last Posted Date
- 2016-10-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 48
- Registration Number
- NCT01365533
- Locations
- 🇨🇦
Nycomed investigational site, Quebec, Canada
Bioequivalence Study of Fixed-dose Combinations and Coadministered Individual Tablets of Saxagliptin/Metformin-Brazil
Phase 1
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: Saxagliptin/metformin fixed-dose combination (FDC)Drug: Saxagliptin/Metformin FDC
- First Posted Date
- 2011-06-03
- Last Posted Date
- 2015-05-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 112
- Registration Number
- NCT01365091
- Locations
- 🇧🇷
Local Institution, Campinas, Sao Paulo, Brazil
Long-tErm Follow-uP of antithrombotIc Management Patterns In Acute CORonary Syndrome Patients in Asia
Completed
- Conditions
- Acute Coronary Syndrome
- First Posted Date
- 2011-05-26
- Last Posted Date
- 2014-06-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 13011
- Registration Number
- NCT01361386
- Locations
- 🇻🇳
Research Site, Hue, Vietnam
New Breath Actuated MDI Symbicort Compared to Symbicort pMDI and Budesonide pMDI for 12 Weeks Twice a Day
- First Posted Date
- 2011-05-25
- Last Posted Date
- 2014-03-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 214
- Registration Number
- NCT01360021
- Locations
- 🇷🇺
Research Site, Moscow, Russia, Russian Federation
Determining Highest Dose Administration of TC-5214 and Evaluating Effect on the Electrical Activity in the Heart
Phase 1
Terminated
- Conditions
- Healthy Male
- Interventions
- First Posted Date
- 2011-05-25
- Last Posted Date
- 2012-12-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 16
- Registration Number
- NCT01359618
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Association Between Low Dose Acetylsalicylic Acid (ASA) and Proton Pump Inhibitors and Risk of Acute Myocardial Infarction or Coronary Heart Disease Death
Completed
- Conditions
- Coronary DeathNonfatal Myocardial Infarction
- First Posted Date
- 2011-05-25
- Last Posted Date
- 2012-11-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 42542
- Registration Number
- NCT01360073
- Locations
- 🇸🇪
Research Site, Molndal, Sweden
Association Between Low Dose Acetylsalicylic Acid (ASA) and Proton Pump Inhibitors and Risk of Acute Myocardial Infarction or Coronary Death
Completed
- Conditions
- Nonfatal Myocardial InfarctionCoronary Death
- First Posted Date
- 2011-05-25
- Last Posted Date
- 2012-11-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 39513
- Registration Number
- NCT01360047
- Locations
- 🇪🇸
Research Site, Madrid, Spain
Validation of the Spanish Version of the Clinically Useful Depression Outcome Scale (CUDOS) Scale
Completed
- Conditions
- Unipolar Depression
- First Posted Date
- 2011-05-25
- Last Posted Date
- 2011-12-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 330
- Registration Number
- NCT01360307
- Locations
- 🇪🇸
Research Site, Vigo, Spain
Assessment of Pharmacokinetics of a Single Oral Dose of VIMOVO in Healthy Adult Volunteers
Phase 1
Completed
- Conditions
- Juvenile Idiopathic Arthritis
- First Posted Date
- 2011-05-23
- Last Posted Date
- 2012-06-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 28
- Registration Number
- NCT01358383
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States